Chronic Resveratrol Consumption Improves Brachial Flow-mediated Dilatation in Healthy Obese Adults
Overview
Authors
Affiliations
Background: We have previously demonstrated acute dose-dependent increases of flow-mediated dilatation (FMD) in the brachial artery after resveratrol consumption in mildly hypertensive, overweight/obese adults. Resveratrol supplementation has also been shown to increase cerebral blood flow acutely, without affecting cognition.
Objectives: To evaluate the effects of chronic resveratrol supplementation on both FMD and cognitive performance.
Method: Twenty-eight obese but otherwise healthy adults (BMI: 33.3 ± 0.6 kg/m) were randomized to take a single 75 mg capsule of trans-resveratrol (Resvida) or placebo daily for 6 weeks each in a double-blind crossover supplementation trial. Blood pressure, arterial compliance, FMD, and performance on the Stroop Color-Word Test were assessed at the end of each 6-week intervention period while fasted and at least 18 h after taking the last daily capsule. An additional capsule of the same supplement was then taken. FMD assessment was repeated 1 h later.
Results: Chronic resveratrol supplementation for 6 weeks was well tolerated and resulted in a 23% increase in FMD compared with placebo (P=0.021, paired t-test). The extent of increase correlated negatively with baseline FMD (r=-0.47, P=0.01). A single dose of resveratrol (75 mg) following chronic resveratrol supplementation resulted in a 35% greater acute FMD response than the equivalent placebo supplementation. These FMD improvements remained significant after adjusting for baseline FMD. Blood pressure, arterial compliance, and all components of the Stroop Color-Word Test were unaffected by chronic resveratrol supplementation.
Conclusion: Daily resveratrol consumption was well tolerated and has the potential to maintain healthy circulatory function in obese adults.
Lazarova M, Stefanova M, Tsvetanova E, Georgieva A, Tasheva K, Radeva L Int J Mol Sci. 2024; 25(23).
PMID: 39684486 PMC: 11641279. DOI: 10.3390/ijms252312777.
Grzeczka A, Graczyk S, Kordowitzki P Cells. 2024; 13(20.
PMID: 39451250 PMC: 11505706. DOI: 10.3390/cells13201732.
Theodoridis X, Chourdakis M, Papaemmanouil A, Chaloulakou S, Papageorgiou N, Georgakou A Life (Basel). 2024; 14(9).
PMID: 39337992 PMC: 11433244. DOI: 10.3390/life14091210.
Addressing the Missing Links in Cardiovascular Aging.
Dinetz E, Zeballos-Palacios C, Martinez C Clin Interv Aging. 2024; 19:873-882.
PMID: 38774249 PMC: 11107914. DOI: 10.2147/CIA.S457180.
Godos J, Romano G, Gozzo L, Laudani S, Paladino N, Dominguez Azpiroz I Front Pharmacol. 2024; 15:1368949.
PMID: 38562461 PMC: 10982351. DOI: 10.3389/fphar.2024.1368949.